Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Completed enrollment in pivotal Phase 3 DURAVYU™ trials for diabetic macular edema.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Completed enrollment in pivotal Phase 3 DURAVYU™ trials for diabetic macular edema
- Enrollment milestone advances the program toward clinical data readouts and potential regulatory submission
- DURAVYU™ progress could expand EyePoint’s ophthalmology pipeline and future commercial opportunity
Item EX-99.1 · Exhibit EX-99.1
- COMO and CAPRI fully enrolled with over 480 participants in five months, reducing enrollment execution risk for DME Phase 3
- Topline 56-week data expected in 4Q 2027, making clinical readouts a key long-term valuation catalyst
- DURAVYU 2.7mg uses six-month redosing versus aflibercept control, targeting a major treatment-burden advantage if non-inferiority is achieved
- DSMC recommended continuation of wet AMD and DME programs without protocol changes, supporting near-term trial continuity
- DURAVYU remains investigational; approval, efficacy, safety, manufacturing, and financing risks remain material for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.